56.29
+1.1387(+2.06%)
Currency In USD
| Previous Close | 55.15 |
| Open | 55.69 |
| Day High | 56.79 |
| Day Low | 55.08 |
| 52-Week High | 63.5 |
| 52-Week Low | 26.2 |
| Volume | 259,669 |
| Average Volume | 654,039 |
| Market Cap | 3.3B |
| PE | -13.6 |
| EPS | -4.14 |
| Moving Average 50 Days | 40.14 |
| Moving Average 200 Days | 38.95 |
| Change | 1.14 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $2,651.38 as of October 20, 2025 at a share price of $56.289. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $1,062.65 as of October 20, 2025 at a share price of $56.289.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
GlobeNewswire Inc.
Oct 10, 2025 8:01 PM GMT
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
GlobeNewswire Inc.
Oct 09, 2025 1:52 AM GMT
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
GlobeNewswire Inc.
Oct 08, 2025 8:01 PM GMT
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory